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Truncating mutation in the autophagy gene UVRAG
confers oncogenic properties and chemosensitivity
in colorectal cancers
Shanshan He1, Zhen Zhao1, Yongfei Yang1, Douglas O’Connell1, Xiaowei Zhang1, Soohwan Oh1, Binyun Ma1,
Joo-Hyung Lee1, Tian Zhang1, Bino Varghese2, Janae Yip1, Sara Dolatshahi Pirooz1, Ming Li3, Yong Zhang4,
Guo-Min Li5, Sue Ellen Martin6, Keigo Machida1 & Chengyu Liang1
Autophagy-related factors are implicated in metabolic adaptation and cancer metastasis.
However, the role of autophagy factors in cancer progression and their effect in treatment
response remain largely elusive. Recent studies have shown that UVRAG, a key autophagic
tumour suppressor, is mutated in common human cancers. Here we demonstrate that the
cancer-related UVRAG frameshift (FS), which does not result in a null mutation, is expressed
as a truncated UVRAGFS in colorectal cancer (CRC) with microsatellite instability (MSI), and
promotes tumorigenesis. UVRAGFS abrogates the normal functions of UVRAG, including
autophagy, in a dominant-negative manner. Furthermore, expression of UVRAGFS can trigger
CRC metastatic spread through Rac1 activation and epithelial-to-mesenchymal transition,
independently of autophagy. Interestingly, UVRAGFS expression renders cells more sensitive
to standard chemotherapy regimen due to a DNA repair defect. These results identify UVRAG
as a new MSI target gene and provide a mechanism for UVRAG participation in CRC
pathogenesis and treatment response.
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C
olorectal cancer (CRC) remains one of the most wide-
spread malignancies worldwide1. Approximately 15% of
sporadic CRC and 90% of Lynch syndrome (hereditary
nonpolyposis colorectal cancer) exhibit a microsatellite instability
(MSI) phenotype, caused by a deficiency in DNA mismatch repair
(MMR) that progresses with a high rate of insertions/deletions to
repetitive DNA sequences, termed microsatellites2. Increasing
evidence suggests that MMR deficiency per se is not sufficient
to drive cell transformation and tumorigenesis, but that
microsatellite mutations in a limited number of target genes
might be positively selected during tumour development and
underlie MSI-associated pathogenesis and treatment response3,4.
Frameshift (FS) mutations of several autophagy-related genes,
including Atg2b, Atg5, Atg9b, Atg12 and UVRAG (ultraviolet
irradiation resistance-associated gene)5–7, were recently reported
in gastric cancer and CRC with MSI. Nevertheless, the functional
consequences and key molecular events downstream of these
mutations have not been extensively investigated.
Our previous studies have established UVRAG as a critical
regulator of intracellular membrane trafficking, including
autophagy and chromosomal stability6,8–16. UVRAG contains
four functional domains, that is, a proline-rich domain, a lipid-
binding C2 domain, a Beclin1-binding coiled-coil domain (CCD)
and a C-terminal domain presumed to be unstructured and
involved in centrosome integrity and DNA damage repair
(Supplementary Fig. 1a)12,17. Importantly, all the different
activities of UVRAG are functionally independent, suggesting
biological interaction and coordinated regulation of the different
processes under diverse environmental cues. Although most
cellular studies to date have considered UVRAG as a tumour
suppressor in human cancers18, the genetic linkage of UVRAG
mutations in major tumour types and the significance
of these mutations in tumour pathogenesis remains less
understood.
Here we show that MSI CRCs with the FS mutation in UVRAG
express a truncated UVRAG protein, referred to here as
UVRAGFS. In addition to losing the wild-type (WT) UVRAG
functions, this nonsense mutant acts as a dominant-negative
mutant and contributes to the oncogenesis and tumour metastasis
of CRC, likely by antagonizing the activity of UVRAGWT as a
tumour suppressor. UVRAGFS expression also increases the
sensitivity to anticancer agents such as 5-fluorouracil (5-FU),
oxaliplatin and irinotecan, routinely prescribed as adjuvant
therapies for CRC patients. Our data thus identified the
underlying pathogenic mechanisms beyond autophagy that are
associated with UVRAGFS-positive cancers and suggest that
expression of UVRAGFS might also be a predictive factor for
chemotherapy response.
Results
UVRAG A10 DNA microsatellite mutation in MSI CRC. The
human UVRAG gene contains a tract of A10 mononucleotide
repeats in exon 8, spanning codons 234–237 (50-AAA AAA AAA
AGT-30; Supplementary Fig. 1a,b). Using seven MSIþ CRC cell
lines (HCT15, HCT116, KM12, LIM2405, LS180, RKO and
SW48) and genomic sequencing, we confirmed, as reported
previously6,7,16, the heterozygous FS deletion of one nucleotide
(A) in the UVRAG A10-coding repeat in most tested MSIþ CRC
cells, with the exception of HCT15 and SW48. In contrast, MSS
(microsatellite stable) cells, including COLO205, HCC2998,
HT29, SW480 and SW620, contained only WT coding repeats
(Fig. 1a). The FS mutation was predicted to produce a premature
stop codon and therefore a truncated UVRAG7 (referred here as
UVRAGFS; Supplementary Fig. 1a,b). To assess whether this
mutation is indeed expressed in MSI cells, we generated an
antibody specifically recognizing UVRAGFS, but not UVRAGWT,
using the FS-derived neopeptide (234KKKVNACS241) as antigen
(Supplementary Fig. 1b,c). UVRAGFS expression was detected in
all MSI cell lines carrying the FS mutation, but not in MSI or MSS
cells that are WT for UVRAG (Fig. 1b). Notably, the overall
expression of UVRAGWT was diminished in MSI cells with the FS
mutation (Fig. 1b), and the levels of UVRAGFS were inversely
correlated with the expression of UVRAGWT in all tested cell
lines (Fig. 1c). This was consistent with the UVRAG expression
profile from the CRC cell lines of the NCI-60 panel19. Therein, a
significant reduction of UVRAGWT expression was detected in
UVRAGFS-positive KM12 and HCT116 CRC cells compared with
other CRC cells without UVRAGFS (Supplementary Fig. 1d). In
addition, the UVRAG FS mutation was present in one of the four
analysed cases of human primary CRC with MSI (fourth column
in Fig. 1d), but not in primary MSS CRC or in normal colorectal
mucosa (Fig. 1d, Supplementary Table 1). This is in line with a
previous report2a that evaluated the mutation frequencies in 137
genes in MSI cancers, revealing the high frequency of the A10
UVRAG FS mutation that was found in 33% CRC, 8%
endometrial and 7.8% gastric cancers with MSI (Supplementary
Fig. 1e). Whole-genome sequencing analysis of a large cohort of
gastric cancers (Pfizer and UHK; n¼ 100) also confirmed the
presence of the UVRAG FS mutation in MSI gastric cancer
(40%)20. Collectively, these results indicate that the frameshift
UVRAG mutation is likely selected and is expressed as a truncated
UVRAG protein in MSI tumours.
Oncogenic property of the UVRAGFS mutation. To probe
whether the UVRAGFS mutant represents a mere loss of WT
function11 as occurs with most other tumour suppressors, or
imparts oncogenic properties, we established MSS SW480 and
MSI HCT116 cell lines stably expressing Flag-tagged UVRAGWT
and UVRAGFS at equivalent levels (Supplementary Fig. 2a,d).
UVRAGFS-transduced cells showed increased proliferation and
enhanced anchorage-independent growth in soft agar
(Supplementary Fig. 2a–e), independently of the tissue of origin
(Supplementary Fig. 2f,g). Subcutaneous transplantation in
athymic nude mice of UVRAGFS SW480 cells resulted in
tumour formation with accelerated kinetics (Supplementary
Fig. 2c). To further test whether expression of UVRAGFS is
sufficient to transform noncancerous cells, we used NIH3T3
mouse embryonic fibroblasts stably expressing UVRAGWT or
UVRAGFS (Fig. 2a). Compared with control (3T3.Vec),
UVRAGFS–3T3 cells had elevated growth rate, formed larger
colonies when plated at low density and induced anchorage-
independent growth, whereas UVRAGWT exerted the opposite
effects (Fig. 2a–c). The tumour growth rate and mean tumour
volume were drastically increased when 3T3–UVRAGFS cells
were injected into nude mice (Fig. 2d). Immunohistological
analyses of tumour xenografts showed UVRAGFS expression and
enhanced mitotic index and number of Ki67þ (proliferating)
cells in UVRAGFS tumours (Fig. 2e). CRC primary tumours with
the FS mutation also had increased Ki67 staining (Fig. 1d).
Altogether, these data indicate a strong association of the
cancer-derived UVRAGFS with a tumorigenic phenotype.
Dominant-negative effect of UVRAGFS on autophagy activa-
tion. UVRAGFS retains the N-terminal proline-rich and C2
domains, and the partial CCD required for Beclin1-mediated
autophagy (Supplementary Fig. 1a)10,12,21–23. To determine
whether UVRAGFS retained its autophagy activity, we measured
the subcellular distribution of the autophagy marker green-
fluorescent protein (GFP)-LC3 and the levels of the
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autophagosome-associated lipidated LC3 (LC3-II)24,25 in
noncancerous NIH3T3 cells. As shown previously10,12,26,
UVRAGWT or rapamycin markedly promoted autophagy, as
evidenced by increased GFP–LC3 puncta per cell, increased
LC3-II conversion and increased response to the late-stage
autophagy inhibitor Bafilomycin A1 (Fig. 3a,b). In sharp contrast,
UVRAGFS did not demonstrate any proautophagic activity.
Furthermore, UVRAGWT autophagy-promoting activity was
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Figure 1 | Identification of UVRAG FS mutation in CRC cell lines and primary tumours. (a) Sequencing analysis of UVRAG at the location of the A10
repeat in MSS (HCC2998, COLO205, SW620, SW480 and HT29) and MSI (HCT15, SW48, HCT116, RKO, LIM2405, LS180 and KM12) CRC cell lines.
Arrows indicate the heterozygous deletion of one A in UVRAG A10 in MSI cell lines. (b,c) Wild-type (WT) and FS mutant UVRAG protein expression in MSS
and MSI CRC cell lines. Whole-cell lysates (WCL) of MSS and MSI CRC cell lines were immunoprecipitated with anti-UVRAGFS followed by
immunoblotting with anti-UVRAGFS, or they were directly probed with antibodies targeting UVRAGWT or g-H2AX. Actin served as a loading control.
Densitometric quantification of protein expression is shown in (c). Dash lines indicate average band intensities of all the tested cell lines. Note reduced
UVRAGWT expression in MSI CRC cells expressing UVRAGFS. (d) H&E (first row) and immunohistochemical analysis of UVRAG (second row), Ki67 (fourth
row), and g-H2AX (5th row) in paired human primary CRC specimen obtained from three separate patients with their corresponding status of UVRAG FS
mutation (third row) provided. The bar plots (right) are the quantification of the levels of Ki67 and g-H2AX (denoted by arrows) in the paired tissues with
WT or mutant UVRAG. HPF, high-power field. ***Po0.001 (Mann–Whitney test); Scale bar ,50 mm.
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abrogated when UVRAGFS was added to the cells dose
dependently (Supplementary Fig. 3a). UVRAG interacts with
Beclin1 through their respective CCD, resulting in activation of
Beclin1-associated Vps34 kinase27. On UVRAGFS expression, the
endogenous association between UVRAGWT and Beclin1 was
diminished, and UVRAGFS was able to sequester the Beclin1 and
UVRAG proteins in vivo, in line with its dominant-negative effect
(Supplementary Fig. 3b, Fig. 3c). Accordingly, Vps34 enzymatic
activity was significantly reduced in UVRAGFS cells (Fig. 3d), as
illustrated by decreased punctate staining of the Vps34 kinase
product, phosphatidylinositol 3-phosphate28. Impaired autophagy
was also observed in vivo in NIH3T3 tumour xenografts expressing
UVRAGFS (Fig. 2e), showing increased levels of p62, an autophagic
substrate29. To explore whether autophagy inhibition underlies
UVRAGFS-mediated oncogenesis, we examined the transforming
effect of UVRAGFS in autophagy-null Atg5-deficient MEFs29.
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b-tubulin serves as a loading control. *Po0.05; **Po0.01. (b) NIH3T3 cells described above were plated at low density (2,500 cells per 10-cm plate),
grown for 14 days then fixed and stained with crystal violet. (c) Anchorage-independent growth induced by UVRAGFS. NIH3T3 cells in (a) were seeded in
0.3% top agar and incubated for 20 days. UVRAGFS-expressing cells formed larger and greater number of colonies in soft agar. Representative images of
colonies are shown and the quantitative results of colony numbers were obtained from 10 randomly chosen HPF. Data represent the means±s.d. (n¼4).
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UVRAGFS promoted cell proliferation (Fig. 3e) and colony growth
in soft agar (Fig. 3f–h), irrespective of the autophagy status.
These data support a direct role of UVRAGFS in promoting
tumorigenesis independently of autophagy.
UVRAGFS induces chromosomal instability and centrosome
amplification. Because the role of UVRAG in cancer has been
linked to its ability to maintain chromosomal stability17, we
investigated the effect of UVRAGFS on overall chromosomal
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stability in genetically stable mouse embryonic stem cells. Spectral
karyotyping analysis showed that, unlike control cells that were
mostly diploid, UVRAGFS-embryonic stem cells were highly
heterogeneous with respect to both structural and numerical
aberrations as compared with the vector control (Fig. 4a,
Supplementary Fig. 4a) with a greater than sevenfold increase
in aneuploidy in UVRAGFS cells (Supplementary Fig. 4b). These
results indicate that UVRAGFS elicits severe chromosomal
instability and aneuploidy. To validate this, we analysed the
Pfizer and UHK cohort20 of gastric cancers, and observed
significantly enhanced chromosomal rearrangement in UVRAGFS
MSI gastric cancers as compared with UVRAGWT MSI gastric
cancers (Fig. 4b). In fact, UVRAGFS gastric cancers had
substantially more protein-altering mutations and single-
nucleotide variants than UVRAGWT MSI and MSS gastric
cancers (Supplementary Fig. 4c). Moreover, the FS mutation
appeared to be more frequent in gastric cases with advanced
tumour, node, metastasis stage (Supplementary Fig. 4d). Thus,
UVRAGFS may predispose MSI cancers to increased genetic
instability and cancer progression.
UVRAGWT has been shown to associate with the centrosome
protein CEP63 (ref. 17), contributing to chromosomal stability by
preventing centrosome overduplication17. UVRAGFS expression
in SW480 cells was sufficient to induce a marked increase in the
incidence and degree of centrosome amplification compared with
control (Fig. 4c). Consistent with the consensus that centrosome
amplification causes erroneous chromosomal segregation30, we
detected spindle malformation, chromosomal missegregation and
prolonged mitosis in UVRAGFS clones, whereas UVRAGWT
clones behaved in the opposite manner (Fig. 4d, Supplementary
Fig. 5a). Unlike WT, UVRAGFS was unable to associate with
CEP63 (Fig. 4e), failing to colocalize with CEP63 and the
centrosome marker, g-Tubulin (Fig. 4f). UVRAGFS disrupted
UVRAGWT-CEP63 interaction (Fig. 4g) and displaced
UVRAG from the centrosome in a dominant-negative manner
(Supplementary Fig. 5b). These results indicate that centrosome
amplification induced by UVRAGFS may play a role in
UVRAGFS-associated chromosomal aneuploidies.
UVRAGFS promotes cell invasion and metastasis outgrowth.
Centrosome amplification per se has been shown to promote cell
invasion through inappropriate microtubule nucleation and
Rac-1 activation31, a small GTPase important for the control of
cell invasiveness and metastasis32,33. Indeed, pull-down assay in
UVRAGFS SW480 cells detected a more than twofold Rac1
activation, which could be blocked by Taxol, but not by the
autophagy inhibitor chloroquine or the anticancer reagent 5-FU
(Fig. 5a), indicating a requirement for dynamic microtubules.
Consistent with increased Rac1 activation, UVRAGFS enhanced
the cell motility of SW480 cells in a wound-healing assay, which
was inhibited by Taxol (Fig. 5b). It also enhanced HCT116 cell
migration through a collagen matrix, whereas UVRAGWT exerted
an inhibitory effect (Supplementary Fig. 6a,b). Spleen injection of
non-metastatic SW480 cells expressing UVRAGFS into nude mice
resulted in a higher incidence of liver metastasis and a greater
number of colonization in the lungs, kidney and peritoneum,
whereas no colonization was found in the control group
(Fig. 5c,d, Supplementary Fig. 6c). UVRAGFS-induced tumour
metastases were confirmed in an independent mouse metastasis
model with SW480 cells expressing GFP–UVRAGFS, as
determined by bioluminescence imaging of metastatic lesions
(Supplementary Fig. 6d). These results indicate that UVRAGFS
enhances the metastatic capacity of CRC cells.
Autophagy has been postulated to be exploited by metastatic
tumours to survive unfavourable conditions34. Nevertheless,
UVRAGFS-metastatic tumours displayed higher levels of p62
than primary tumours, indicative of suppressed autophagy
(Fig. 5e). Moreover, UVRAGFS metastatic tumours exhibited
decreased apoptosis, as shown by decreased caspase 3 activation
(Fig. 5e). Hence, in this context, autophagy is not the driving
mechanism for metastatic colonization in CRC. Nevertheless, we
observed other pathological differences that may account for
increased metastasis on UVRAGFS expression. The colonized
CRC tumours had reduced levels of the epithelial cell marker
E-cadherin but increased levels of the mesenchymal markers,
N-cadherin and vimentin (Fig. 5e), suggesting an induction of
epithelial-mesenchymal transition (EMT) in the process of
colonization. Indeed, expression of UVRAGFS in SW480 cells
downregulated E-cadherin and upregulated N-cadherin and
vimentin, whereas expression of UVRAGWT had the opposite
effect (Fig. 5f). Importantly, UVRAGFS-associated EMT was
efficiently reverted by Taxol without affecting Taxol-induced cell
death (Fig. 5f, Supplementary Fig. 6f). Consistent with our in vitro
observations, the primary MSI colon tumour with UVRAGFS
exhibited elevated expression of N-cadherin and vimentin, along
with significant reduction in E-cadherin levels, which were not
detected in tumours with UVRAGWT (Supplementary Fig. 6e).
These results indicate that UVRAGFS expression, which
triggers centrosome amplification and Rac1 activation, can
activate the EMT program and promote cell invasion and
tumour metastasis.
UVRAGFS affects CRC response to chemotherapy. We next
investigated the possible clinical relevance of UVRAGFS by testing
the response of CRC to 5-FU chemotherapy, the first-line
treatment for CRC patients, using a tumour xenograft
model. Surprisingly, UVRAGFS expression significantly increased
tumour sensitivity to 5-FU treatment with an approximate
10-fold reduction in tumour volumes after a 4-week adminis-
tration of 5-FU (Fig. 6a), compared with a less than twofold
reduction in the control group (Fig. 6a–c). Histological analyses
revealed a significant reduction in cell proliferation and
an increase in the number of cells undergoing apoptosis in
5-FU-treated UVRAGFS tumours, in concordance with induced
tumour shrinkage (Fig. 6d). In addition, UVRAGFS expression
in CRC cells markedly increased their sensitivity to other
DNA-based cytotoxic anticancer agents, including oxaliplatin and
irinotecan, as shown by reduced rates of clonogenic survival,
whereas UVRAGWT cells were resistant to the drugs (Fig. 6e).
To examine the unexpected role of UVRAGFS in tumour
chemosensitivity, we measured the levels of g-H2AX, a sensitive
marker of double strand breaks (DSBs)35, and observed that
UVRAGFS SW480-tumours accumulated higher levels of
g-H2AX than the controls, which further increased with 5-FU
that produces DNA strand breaks (Fig. 6d). Consistent with our
observation in xenograft tumours, UVRAGFS expression resulted
in a significant increase of g-H2AX foci and levels in SW480 CRC
cells (Supplementary Fig. 7a,b). Furthermore, the overall levels of
g-H2AX were higher in MSI CRC cell lines expressing UVRAGFS
compared with the WT counterparts, and likewise, were
significantly different between UVRAGFS-positive and -negative
primary tumours (Fig. 1b,d). Adding UVRAGWT to UVRAGFS-
positive HCT116 and RKO cells at different doses clearly
suppressed the levels of DSBs (Supplementary Fig. 7c),
highlighting a direct involvement of UVRAGFS in genetic
stability. To determine whether the observed accumulation of
DSB in UVRAGFS cells reflects impaired DNA repair, we
measured unrepaired DSBs after ionizing radiation (IR) using
the comet assay. We found that IR induced comparable levels of
DNA damage in vector, UVRAGWT and UVRAGFS cells (10 min
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(b) Chromosomal rearrangement and single-nucleotide variants (SNVs) in UVRAGFS gastric cancer. Representative Circos plots of the UVRAGWT
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post-IR in Fig. 7a). However, a high persistence of comet tails was
observed 24 h post-irradiation in UVRAGFS cells, whereas
UVRAGWT cells have repaired most of the damaged DNA.
These data indicate that UVRAGFS disrupts the rapid repair
process of DSBs. The inhibitory effect of UVRAGFS on DSB
repair was also detected in the autophagy-competent Atg3þ /þ
and the autophagy-null Atg3 / cells (Supplementary Fig. 7d),
suggesting minimal participation of autophagy in the elevated
DNA damage induced by UVRAGFS expression.
UVRAGFS is defective in the repair of DNA damage. We then
asked whether UVRAGFS-associated DNA damage results from
suppression of UVRAGWT function, which is known to promote
DSB repair by NHEJ (non-homologous end joining) through
interaction with the Ku70/Ku80/DNA–PKcs complex17. Unlike
with UVRAGWT, no physical interactions between UVRAGFS
and DNA–PK proteins could be detected (Supplementary
Fig. 7e). Moreover, UVRAGFS failed to translocate to sites of
laser-induced DNA damage stripes containing g-H2AX, whereas
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UVRAGWT was enriched at the damaged sites of DSBs
(Supplementary Fig. 7f). As expected, ectopic expression of
UVRAGFS blocked UVRAG-Ku70/Ku80 interaction, and
disturbed Ku/DNA–PKcs complex formation after IR,
concomitant with increased sequestration of UVRAGWT, again
highlighting the dominant-negative effect of the FS mutation
(Fig. 7b). To further establish a link between UVRAGFS and the
DNA-damaging phenotype observed, we evaluated the DNA
repair capacity in UVRAGFS cells, using a NHEJ repair reporter,
the EJ5-GFP system36. Expression of UVRAGFS alone markedly
reduced the rate of NHEJ repair by over 50%, whereas it had no
discernable effect on DNA homologous recombination repair
(Fig. 7c). Treating cells with Nu7441, a specific inhibitor of DNA–
PK37, abolished the effect of UVRAGFS (Supplementary Fig. 7g).
These results indicate that UVRAGFS-induced DNA damage is
dependent on the inactivation of DNA-PK-mediated NHEJ,
which renders tumour cells more sensitive to DNA-damaging
chemotherapy.
Discussion
Microsatellite instability as a result of MMR deficiency has been
widely observed in human CRC. However, little is known of the
biological consequences and pathogenic mechanisms associated
with the selective gene targeting by MSI. Herein, we demonstrate
that the autophagic tumour suppressor UVRAG represents a new
bona fide MSI target gene in CRC and, likely, other MSI-related
tumours, and that the truncating mutation in UVRAG enhances
cellular transformation and penetrance of CRC tumour by
interfering with the tumour-suppressing functions of UVRAGWT
in a dominant-negative manner. Furthermore, mutated UVRAG
alleles sensitize CRC to DNA damage-inducing treatment,
making the UVRAGFS genotype a possible predictive factor for
the response to chemotherapy treatment.
In this study, we found that the heterozygous deletion of the
UVRAG A10 exonic DNA repeat resulted in the expression of a
truncated protein using an antibody specifically recognizing
UVRAGFS, and that it influences the expression and function of
UVRAGWT in a series of CRC cell lines and primary CRCs.
Contrary to our findings, a previous study7 showed by
immunoblotting that the levels of UVRAGWT appeared to be
unaffected by the occurrence of the UVRAG FS mutation in three
MSI CRC cell lines carrying the FS mutation (HCT116, LoVo and
RKO), two of which having also been used in our study (Fig. 1b).
While it is difficult to explain the discrepancy between this
published work and ours, it might be due to differences in
experimental design and/or to different sources or passage
numbers of CRC cell lines used in both studies. Nonetheless,
our results are consistent with the gene expression data retrieved
from a GeneChip analysis of NCI-60 cancer cell lines from TSRI
(The Scripps Research Institute; data are accessible at BioGPS:
http://biogps.org), correlating reduced UVRAGWT expression in
T
ai
l d
is
tr
ib
ut
io
n 
(%
)
0
50
100
Type I
Type I Type II Type III
Type II
Type III
**
**
SW480 Cell
U
V
R
A
G
W
T
U
V
R
A
G
W
T
U
V
R
A
G
F
S
U
V
R
A
G
F
S
U
V
R
A
G
W
T
U
V
R
A
G
F
S
V
ec
V
ec
V
ec
No IR 10 min post IR 24 h post IR
**
**
**
**
0 4 10 μg
IP: UVRAG
IB: Ku70
IP:UVRAG
IB: Flag
WCL
IB:Ku 70
WCL
IB: Flag
WCL
IB:Tubulin
IP: UVRAG
IB: Ku80
IB: Ku70/80
IP: DNA-PKcs I
P
W
C
Ls
UV
RA
G
FSVe
c
UV
RA
G
FSVe
c
0
50
100
150 NHEJ HR
**
90 -
35 -
90 -
35 -
50 -
80 -
80 -
70 -
NS
D
N
A
 r
ep
ai
r 
ac
tiv
ity
(%
 o
f c
on
tr
ol
)
No IR 10 min post IR 24 h post IR
V
ec
U
V
R
A
G
W
T
U
V
R
A
G
F
S
a
b
c
Flag-UVRAGFS
Figure 7 | UVRAGFS inhibits NHEJ repair. (a) Neutral comet assay shows a delay of DNA DSBs repair in UVRAGFS cells. SW480 cells stably expressing
empty vector (first row), UVRAGWT (second row) or UVRAGFS (third row) were treated with 1 Gy IR. The DNA damage levels of the cells before IR,
10 min post IR and 24 h post IR were assessed. Representative comet images are shown in the left panel and quantifications are shown on the right.
(b) UVRAGFS inhibits UVRAG interaction with Ku70 and Ku80 and the interaction of Ku70/80 with DNA–PKcs. The 293T cells transfected with increasing
amounts of Flag-UVRAGFS were treated with IR (5 Gy). WCL were immunoprecipitated with anti-DNA–PKcs or anti-UVRAG, followed by immunoblotting
with the indicated antibodies. (c) HEK293 cells stably expressing the EJ5-GFP reporter for NHEJ and the DR-GFP reporter for homologous recombination
(HR) were transfected with an empty vector or Flag-UVRAGFS before the induction of DSBs by SceI transfection. The DNA repair activities as assessed by
the reconstituted GFP signals were quantified by fluorescence-activated cell sorting. Data shown represent mean±s.d. (n¼ 3). **Po0.01.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8839
10 NATURE COMMUNICATIONS | 6:7839 | DOI: 10.1038/ncomms8839 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
a subset of CRC cell lines with the UVRAG FS mutation. Taken as
a whole, our findings and those of others suggest that inactivation
of UVRAG is selected for during the progression of colorectal
tumours, and that UVRAGWT plays a suppressor role in
colorectal tumorigenesis.
Previous studies have indicated that autophagy protects
genomic integrity presumably by removing aged or damaged
proteins and organelles38–40. We observed a significant reduction
of autophagy by UVRAGFS in CRC cells and primary tumours,
which was even greater in the metastases. Of note, a previous
study7 argued that UVRAGFS lost Beclin1-binding activity due to
the frameshift truncation. However, we found that even though
UVRAGFS lost more than 50% of CCD of UVRAGWT, it still
retains a small alpha-helix structure in the CCD and remains
competent for UVRAG and Beclin1 interaction, thereby
neutralizing their proautophagic effect in a dose-dependent
manner. However, autophagy loss could not prevent the
transformed phenotype induced by UVRAGFS, indicative of an
autophagy-independent oncogenic mechanism associated with
UVRAGFS, as previously suggested7.
We found that ectopic expression of UVRAGFS per se in both
embryonic stem cells and cancer cells results in extensive
centrosome amplification and concomitant aneuploidy. Indeed,
this cancer-associated mutated UVRAG, which lacks CEP63-
binding ability, is more than just a relic of UVRAG inactivation, it
instead disturbs the association of endogenous UVRAGWT with
CEP63, presumably by displacing endogenous active UVRAG
from the centrosome and/or by titrating out an unknown
regulator into nonfunctional complexes. This is similar to what
occurs with mutations in other tumour suppressors, such as p53.
Certain mutated forms of p53 have not only lost their tumour-
suppressive function, but have also gained a function as an
oncogene41. Consistent with a previous study demonstrating that
inappropriate microtubule nucleation due to centrosome
amplification enables Rac1 activation and promotes cell
invasion31, we found that UVRAGFS promotes metastatic
outgrowth and EMT properties in a Rac1-dependent manner.
Our mutational and integrative analyses emphasize the critical
role of UVRAGFS and centrosomal stability in the context of
metastatic CRC.
Despite increased oncogenic transformation, UVRAGFS-
expressing tumours appear to be more responsive to chemother-
apy that induces massive DNA damage and replication stress.
Unlike UVRAGWT, UVRAGFS cannot translocate to DSB sites
and its expression further interferes with a functional complex
assembly of DNA-PK, a key effector in the NHEJ pathway. As
NHEJ factors are considered as genome caretakers that guarantee
genomic integrity through the proper repair of DNA lesions, our
data thus provide a potential mechanism by which UVRAGFS
elevates the levels of DNA damage via acting on NHEJ repair and
sensitizes tumour cells to chemotherapy. Thus, UVRAGFS may
represent an important determinant in the treatment response of
CRC tumours.
In summary, we have demonstrated that a cancer-derived
UVRAG truncated mutant plays a role in oncogenic transforma-
tion and tumour metastasis, which explains the selection for its
expression in human CRC cell lines and primary tumours with
MSI. This mutant impairs UVRAGWT function in autophagy
and chromosomal stability. Our findings suggest that UVRAGFS
expression contributes to chemosensitivity through direct
repression of DNA damage repair and ensuing increased cell
death. This regulatory circuit may partially explain the more
favourable prognosis in patients with MSI tumours than in those
with MSS tumours, as previously noted42. It may also have
potential relevance for pharmacogenetic selection of MSI cancer
patients for adjuvant chemotherapy.
Methods
Cell culture, transfection and tumour samples. HeLa (CCL-2), 293T (CRL-
3216), NIH3T3 (CRL-1658), HT29 (HTB-38), RKO (CRL-2577), LS180 (CL-187),
HCT116 (CCL-247), SW480 (CCL-228) were purchased from ATCC. LIM2405,
HCC2998, HCT15, COLO205, SW620, KM12 and SW48 were obtained from
Dr. Guomin Li (University of Kentucky College of Medicine, USA). HeLa, 293T,
immortalized MEF (iMEF), NIH3T3, HT29, RKO, LS180 and HCT116 cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM). LIM2405, HCC2998,
HCT15, COLO205, SW620 and KM12 cells were cultured in Roswell Park
Memorial Institute (RPMI) 1640. SW480 and SW48 were cultured in Leibovitz’s
L-15 in the absence of CO2. All media above were supplemented with 10% fetal
bovine serum (FBS; Invitrogen), 2 mM L-glutamine, and 1% penicillin–
streptomycin (Gibco-BRL). Transfections were performed with FuGENE 6 HD
(Roche) or Lipofectamine 2000 (Invitrogen), following the manufacturer’s
instructions. M059K and M059J cells were cultured as previously described43.
SW480, HCT116, NIH3T3 and HeLa stable cell lines were established using a
standard protocol of selection with 2 mg ml 1 puromycin (Sigma-Aldrich). Mouse
embryonic stem cells were obtained from the Mutant Mouse Regional Resource
Center, and maintained at comparable passage in GMEM (Sigma) with 15% FBS
(Invitrogen), following the Mutant Mouse Regional Resource Center cell culture
protocol (http://www/mmrrc.org/strains/E14/ctr_protocol.pdf). All cell lines used
were mycoplasma free. Paraffin-embedded primary tumours and normal colonic
tissues were obtained from patients undergoing surgery from the USC Norris
Cancer Center Translational Pathology Core, CA, USA. The MSI status was
determined by analyzing a comparable panel of five mononucleotide markers:
NR-27, NR-21, NR-24, BAT-25 and BAT-26 (ref. 44).
Plasmid constructs. The Flag-tagged WT UVRAG and UVRAGFS mutant were
constructed by cloning the cDNA of the WT and truncated UVRAG mutant into
the AflII/NotI sites of the pEF/puro-Flag vector. All constructs were confirmed by
sequencing using an ABI PRISM 377 automatic DNA sequencer (Applied
Biosystems).
Mutation analysis. Genomic DNA and cDNA from cell lines and primary
tumours were amplified by PCR. The primer pair (forward and reverse,
respectively) is: 50-ATGTTTTAAGCCATTATTTA-30 and 50-CGTTCCAGTTC
ATTCTG-30 . PCR products from single clones from every sample were sequenced
using an automated ABI PRISM 377 automatic DNA sequencer.
Antibodies, fluorescent dyes and other reagents. The following antibodies were
used in this study: polyclonal rabbit anti-UVRAG (U7058, Sigma-Aldrich) at
1:1,000; monoclonal mouse anti-UVRAG (SAB4200005, clone UVRAG-11,
Sigma-Aldrich) at 1:200; monoclonal mouse anti-Ku70 (ab-4, Thermo-fisher) at
1:5,000; monoclonal anti-Ku80 (C48E7, Cell Signaling) at 1:1,000; monoclonal
mouse anti-DNA–PKcs (Ab-4, Thermo-fisher) at 1:2,000; monoclonal mouse
anti-g-tubulin (T6557, Sigma-Aldrich) at 1:2,000; Cy3 conjugated anti-g-tubulin
(C7604, Sigma-Aldrich) at 1:500; monoclonal mouse anti-a-tubulin (T6199,
Sigma-Aldrich) at 1:2,000; polyclonal rabbit anti-CEP63 (16268-1-AP,
ProteinTech) at 1:2,000, monoclonal mouse anti-g-H2AX antibody (05–636,
Millipore) at 1:2,000; monoclonal mouse anti-p62 at 1:3,000 (MBL, Japan);
monoclonal mouse anti-LC3 at 1:500 (CAC-CTB-LC3-2-IC; clone: LC3-1703;
Cosmo Bio USA); polyclonal rabbit anti-Ki67 (NB110-89719, Novus) at 1:100;
monoclonal rabbit anti-cleaved caspase-3 (Asp175; #9664, Cell signaling
Technology) at 1:2,000; polyclonal rabbit anti-E-cadherin (20874-1-AP,
Proteintech) at 1:200; polyclonal rabbit anti-N-cadherin (PA5-29570, Pierce)
at 1:1,000; monoclonal mouse anti-vimentin (MA5-11883, Pierce) at 1:1,000;
monoclonal mouse anti-active Rac1-GTP (#26903, NewEast Biosciences) at
1:1,000; mouse anti-Rac-1 (#610650, BD Biosciences); monoclonal anti-Flag
(F3165; clone M2; 1:2,000) were purchased from Sigma-Aldrich; The UVRAGFS
peptide-specific antibody was generated by immunizing rabbits with the UVRAGFS
peptide 234KKKVNACS241, covalently coupled to keyhole limpet haemocyanin
(KLH) and purchased from GenicBio. Horseradish peroxidase (HRP)-labelled
or fluorescently labelled secondary antibody conjugates were purchased from
Molecular Probes (Invitrogen, USA). Purified rabbit IgG as purchased from Pierce.
Unless otherwise stated, all chemicals were purchased from Sigma-Aldrich.
Immunofluorescence and confocal laser-scanning microscopy. For the
centrosome-related studies, cells were fixed with cold methanol for 10 min at
 20 C, while 4% paraformaldehyde (20 min at room temperature) was used for
the other studies. After fixation, cells were permeabilized with 0.2% Triton X-100
for 8 min and blocked with 10% goat serum (Gibco-BRL) for 1 h. Primary antibody
staining was carried out using antiserum or purified antibody in 1% goat serum for
1–2 h at RT, or overnight at 4 C. Cells were then extensively washed with PBS
and incubated with diluted Alexa 488-, Alexa 594- and/or Alexa 633-conjugated
secondary antibodies in 1% goat serum for 1 h, followed by DAPI (40 ,60-diamidino-
2-phenylindole) staining. Cells were mounted using Vectashield (Vector
Laboratories, Inc.). Confocal images were acquired using a Nikon Eclipse C1
laser-scanning microscope (Nikon, PA), fitted with a 60 Nikon objective
(PLAPO, 1.4 NA), and Nikon image software. Images were collected at
512 512-pixel resolution. The stained cells were optically sectioned in the z axis.
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For multichannel imaging, fluorescent staining was imaged sequentially in
line-interlace modes to eliminate crosstalk between the channels. The step size
in the z axis varied from 0.2–0.5 mm to obtain 16 slices per imaged file. All
experiments were independently repeated several times. The investigators
conducted blind counting for quantification. Values indicate the mean±s.d.
of at least three independent experiments.
Histopathology and immunohistochemistry. Tissue sections from the indicated
mouse models were fixed in 10% buffered formalin and embedded in paraffin.
Tissue sections were routinely stained with haematoxylin and eosin. For
immunohistochemistry staining, tissue slides were deparaffinized in xylene and
rehydrated in alcohol. Endogenous peroxidase was blocked with 3% hydrogen
peroxide. Antigen retrieval was achieved using a microwave and 10-mM citric
sodium buffer (pH 6.0). Sections were then incubated overnight at 4 C with
the primary antibody. Antibody binding was detected with Envision Dual Link
System-HRP DAB kit (K4065, Dako). Sections were then counterstained with
haematoxylin. For negative control, the primary antibody was replaced with the
buffer. The mitotic index was quantified by viewing and photographing 10 random
high-power field of each tissue section on a Nikon microscope, using a
40 objective. For evaluation and scoring of immunohistochemical data,
we randomly selected 10 fields within the tumour area under high-power
magnification ( 400) for evaluation. The investigators conducted blind counting
for each quantification-related study.
Immunoblotting and immunoprecipitation. For immunoblotting, polypeptides
were resolved by SDS–PAGE and transferred to a PVDF membrane (Bio-Rad).
Membranes were blocked with 5% non-fat dry milk, and probed with the indicated
antibodies. HRP-conjugated goat secondary antibodies were used (1:10,000,
Invitrogen). Immunodetection was achieved with the Hyglo chemiluminescence
reagent (Denville Scientific), and detected by a Fuji ECL machine (LAS-3000). For
co-immunoprecipitation, cells were lysed in 1% NP40 lysis buffer (25 mM Tris
pH 7.5; 300 mM NaCl, 1 mM EDTA, 1% NP40), supplemented with a complete
protease inhibitor cocktail (Roche). After preclearing with protein A/G agarose
beads for 1 hr at 4 C, whole-cell lysates were used for immunoprecipitation with
the indicated antibodies. Generally, 1–4 mg commercial antibody was added to cell
lysate, which was incubated at 4 C for 8–12 h. After addition of protein A/G
agarose beads, incubation was continued for another 2 h. Immunoprecipitates were
extensively washed with NP40 lysis buffer and eluted with SDS–PAGE loading
buffer by boiling for 5 min before resolution by SDS–PAGE.
Soft agar anchorage-independent growth assay. To evaluate anchorage-
independent colony formation, engineered cells (104) were suspended in complete
medium containing 0.3% Nobel agar (Difco) supplemented with 2 mg ml 1
puromycin and plated in 6-well plates over a basal layer of 0.5% agar in complete
medium. Colonies were scored 21 days after plating and were photographed by
phase-contrast microscopy. Images were captured with the QCapture software
program. Clonogenicity was determined in triplicate experiments.
In vitro wound-healing assay. The cell invasive activity was determined using the
wound-healing assay45. Briefly, cells (2.5 105) were seeded in 12-well slide
chambers and grown into a 100% confluent monolayer culture. The confluent
cell monolayer was scratched with a pipette tip, followed by media replacement.
After 24 h, the width of the mean wound distance was calculated using software
connected to Nikon Eclipse digital inverted microscope. To evaluate the ‘wound
closure’, 10 randomly selected points along each wound were marked, and the
horizontal distance the migrating cells travelled into the wound was measured.
In vitro cell migration assays. A Transwell system (Corning, NY, USA) was used
to evaluate cell migration. The upper and lower chambers were separated by
a polycarbonate membrane with pores of 8-mm coated with fibronectin (BD
Biosciences, CA, USA) on the lower surface. Cells (2 105) suspended in 100 ml
serum-free medium were seeded onto the upper chamber, and 800 ml of medium
with 10% FBS was added to the lower chamber. After 24-h incubation at 37 C with
5% CO2, the medium was removed from the upper chamber. The non-invading
cells on the upper side of the chamber were scraped off with a cotton swab. Cells on
the bottom side of the membrane were fixed, stained with crystal violet and
mounted. The migration activity of cancer cells was determined by counting cells in
10 different viewing fields using a microscope at  200 magnification. Each assay
was repeated three times.
Clonogenic cell survival assay. The log-phased cells were plated in six-well plates
overnight, allowing cells to attach to the plates. After chemotherapy drug treatment
(24 h exposure), cells were trypsinized, counted and replated at appropriate
dilutions for colony formation. After 10–14 days of incubation, colonies were fixed
with methanol/acetic acid (3:1), stained with crystal violet and counted. Plating
efficiency was determined for each individual cell line46 and the surviving fraction
(SF) was calculated based on the number of colonies that arose after treatment,
expressed in terms of plating efficiency. Each experiment was repeated three times.
In vivo tumorigenicity assay. To measure in vivo tumorigenicity, engineered
NIH3T3 and SW480 cells expressing WT or the mutant form of UVRAG (5 106)
were transplanted into the flanks of six-week-old female NCR nude mice (Charles
River). Ten mice per cell line were used. Mice were monitored triweekly for the
development of tumours, and necropsied after a 3-week observation period.
The tumour growth was monitored by measurements of tumour length (L) and
width (W) and tumour volume was calculated47 using the following formula:
Volume¼ 4/3 p (1/2 width)2 1/2 length. All animal studies were performed
in compliance with the University of Southern California Institutional Animal Care
and Use Committee guidelines.
In vivo metastasis assay. A midline incision was made on the left flank, and the
spleen was exteriorized. SW480 cells (106 cells) were injected into the spleen, after
which the wound was closed with surgical metal clips. The mice were sacrificed
after 8 weeks, and their spleen, liver, lungs and lymph nodes were removed and
examined for tumour metastases. The organ specimens were formalin-fixed and
paraffin-embedded for histological analysis. Alternatively, GFP-labelled cells can be
tracked using bioluminescence imaging at the end of experiment. Briefly, mice were
placed in the induction chamber with 2% isoflurane in oxygen. GFP activity was
localized and quantified using an IVIS 200 image system. Images were taken with
an excitation wavelength of 465 and emission wavelength ranging from 500 to 540.
Imaging processing and analysis, including flat fielding, adaptive background
subtraction and spectral unmixing were performed with Living Image 3.0 software.
Autophagy analyses. Quantitative GFP–LC3 light microscopy assay was
performed in NIH3T3 cells expressing the WT or FS mutant of UVRAG, then
transfected with a GFP–LC3-expressing plasmid24. Autophagy was then induced
by 100 nM rapamycin (Sigma-Aldrich) for 2–6 h in DMEM containing 1% FBS.
For autophagic flux, the rapamycin-treated cells were cultured in DMEM
containing 100 nM Bafilomycin A1 for 2 h. LC3 mobility shift and levels were
detected by immunoblotting12,48.
Neutral comet assay. Neutral comet assay was performed using the CometAssay
kit (Trevigen) following the manufacturer’s instruction. Briefly, 10 ml of cell
suspension (105 cells per ml) was carefully mixed with 90 ml of molten LMAgarose.
After solidification, slides were immersed in Lysis Solution at 4 C for 1 h, and
equilibrated in chilled neutral electrophoresis buffer for 30 min. Electrophoresis
was performed in neutral electrophoresis buffer for 1 h with an electric field of
1 volt cm 1. Slides were further treated with DNA Precipitation Solution, followed
by 70% ethanol for 30 min each at room temperature. After air drying, cells were
stained with SYBR Green (1 mg ml 1) or Propidium Iodide (1 mg ml 1). Comet
images were captured using an epifluorescence microscope (Nikon Eclipse C1).
To analyse the images, cells were scored into three categories based on tail length
(no tails, tail length shorter than 20 mm, tail length longer than 20 mm), and
quantified.
Laser microirradiation. Laser microirradiation was done essentially as described
before49. Cells grown on coverslips were incubated for 24 h in medium containing
10 mM BrdU (Sigma-Aldrich). Laser microirradiation was carried out with a Nikon
C1 confocal microscope (Nikon) equipped with a 37 C CO2 chamber and a diode
laser (Melles Griot). DSBs restricted to the laser path were generated across the
nuclei in 50 cells per coverslip, using the 100 oil objective and 30% of laser
power (l¼ 405 nm) for 100 scans. Cells were then returned to tissue culture
incubator at 37 C, fixed 1 h later and analysed by immunofluorescence as
described below. Laser-induced DNA damage was visualized with the g-H2AX
antibody (Millipore) and the UVRAG antibody (Sigma). Images were taken with a
Nikon C1 confocal microscope (Nikon) and Axio Imager 2 (Zeiss).
In vivo DNA DSB Repair. To measure the DNA DSB repair activity, a GFP-based
chromosomally integrated reporter was utilized50. In brief, the HEK293 cells stably
expressing EJ5-GFP reporter were transfected with empty vector or UVRAGFS
plasmid. Two days later, a secondary transfection was performed with the same
plasmids plus an I-SceI expression vector (pCBASce), together with pmCherry as a
transfection indicator. Cells were collected after another 48 h, and analysed by
standard flow cytometry. UVRAG expression was verified by western blotting.
The repair activity of DSB generated by I-SceI was calculated by the percentage of
GFP-positive (repaired) cells in the mCherry-positive cells (transfected).
Chromosomal analysis by SKY. SKY analysis of embryonic stem cells was
performed. Briefly, metaphase chromosome were prepared from exponentially
growing cells after treatment with colcemid (KaryoMAX, GIBCO) at 0.1 mg ml 1
for 1 hr (ref. 51). Cells were swollen in prewarmed 0.56% KCl for 10 min at 37 C,
then carefully fixed in methanol:acetic acid (3:1) overnight and kept at  20 C.
Metaphase spreads were prepared by dropping cells in the fixative onto chilled
Superfrost glass slides (Fisher Scientific) at 25 C and 60% of humidity. After air
drying and pepsin digestion, slides were denatured at 80 C for 5 min, hybridization
was performed using SKY probe (Applied Spectral Imaging, San Diego) and
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fluorescence-conjugated secondary antibodies in accordance with the
manufacturer’s specification. Metaphase images were captured and analysed using
a SpectraCube imaging system and software (Applied Spectral Imaging). At least
20 metaphases from each cell line were scored for chromosomal aberration.
Genomic analysis of publically available datasets. All data for UVRAG
frameshift mutation in human CRC, gastric, and endometrial cancers with MSI
were obtained from SelTarbase (http://www.seltarbase.org/) and primary public
sources6,52–54. All data for DNA sequence alteration, chromosomal structure
variants, and clinical information in gastric cancer were obtained from cBioportal
(http://www.cbioportal.org)55,56 and primary sources57. All statistical analyses were
carried out using the R software package. Circos plots were carried out using Circos
(http://circos.ca/).
Statistical analysis. All experiments were independently repeated at least three
times. To ensure adequate power and decrease estimation error, we used large
sample sizes and multiple independent repeats by independent investigators.
Multiple lines of experiments including different quantification methods were used
for the consistent and mutually supportive results. The sample size was chosen
according to the well-established rule in the literature as well as our ample
experience in previous research. Data are presented as the mean±s.d. Statistical
significance was calculated using the Student’s t-test or one-way analysis of
variance test using GraphPad Prism 5.0 (GraphPad Software, Inc.), unless
otherwise stated. A P value of r0.05 was considered statistically significant58.
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